Angelini Pharma Bulgaria

Angelini Pharma Bulgaria provides well established and innovative products (prescription and OTC drugs, medical devices, food supplements) to major national wholesalers who distribute them to pharmacies and hospitals.

The main therapeutic areas of Angelini Pharma Bulgaria are: CNS, respiratory, gynaecology, orthopaedics, rheumatology, dermatology, HCV and oncology.

The main brands are: Acutil, market leader in the other stimulants market; Piascledine, market leader in the ortho muscolo-skeletal market; Macmiror, market leader in the gynaecological anti-infectives market; Monural, market leader in the urinary anti-infective markets; Harvoni, leader in HCV market; Eclusa, the first pan genotype product in HCV market; Tantum Verde, Erdomed, Polinail, Rosalgin and Trittico are among the main leaders in the reference markets.

BRANDS THERAPEUTIC AREA
Flexodon C, Hyalgan, Hyalone, Hymovis, Piascledine Orthopaedics/Rheumatology
Acutil Cognitive health
Aulin, Neuritogen, Trosicam Pain/Inflammation
Feminella Hereditum, Feminella Hyalosoft, Feminella Vagi C, Feminella Uroforte, Macmiror, Rosalgin, Monural Gynaecology
Micetal, Polinail Dermatology
Trittico, Trittico XR CNS
Glimbax, Tantum Verde Oral Care and Sore Throat
Erdomed, Fluimucil Expectorants
Harvoni, Epclusa HCV
Tantum Flu Cold and Flu
Aloxi, Iclusig, Vellofent Oncology

In 2007 Angelini acquired CSC Pharmaceuticals, a pharmaceutical group active in Central and Eastern Europe, of which Angelini Pharma Bulgaria (ex CSC Pharmaceuticals LTD Bulgaria) was part.
After the acquisition by the Angelini Group, the transfer process began and Angelini Pharma Bulgaria became fully operative in 2011, when the complete portfolio and activities were transferred  to the new trading company.
The acquisition of CSC Pharmaceuticals by Angelini leads new products in the company's portfolio and an increase in sales.

The company employs about 70 people. Today Angelini Pharma Bulgaria is among the first 15 companies on the Bulgarian market  with a turnover of more than 14 M€ (2018).